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OBJECTIVE: The individual components of metabolic syndrome may be independent predictors of mortality in
patients with liver disease. We aimed to evaluate the prevalence of metabolic syndrome and its related components
in hepatitis C virus–infected patients who are not obese and do not have type 2 diabetes.
METHODS: This cross-sectional study included 125 patients infected with hepatitis C virus genotype 1. Metabolic
syndrome was defined according to the International Diabetes Federation. Anthropometric data were measured
according to standardized procedures. Bioimpedance analysis was performed on all patients.
RESULTS: Metabolic syndrome was diagnosed in 21.6% of patients. Of the subjects with metabolic syndrome, 59.3%
had hypertension, 77.8% had insulin resistance, 85.2% were overweight, 48.1% had a high waist circumference,
85.2% had an increased body fat percentage, and 92.3% had an elevated waist:hip ratio. In the bivariate analysis,
female sex (OR 2.58; 95% CI: 1.09–6.25), elevated gamma-glutamyl transferase (cGT) (OR 2.63; 95% CI: 1.04–7.29),
elevated fasting glucose (OR 8.05; 95% CI: 3.17-21.32), low HDL cholesterol (OR 2.80; 95% CI: 1.07–7.16),
hypertriglyceridemia (OR 7.91; 95% CI: 2.88–22.71), elevated waist circumference (OR 10.33; 95% CI: 3.72–30.67),
overweight (OR 11.33; 95% CI: 3.97–41.07), and increased body fat percentage (OR 8.34; 95% CI: 2.94–30.08) were
independent determinants of metabolic syndrome. Using the final multivariate regression model, similar results
were observed for abdominal fat (OR 9.98; 95% CI: 2.63–44.41) and total body fat percentage (OR 8.73; 95% CI:
2.33–42.34). However, metabolic syndrome risk was also high for those with blood glucose $5.55 mmol/L or HDL
cholesterol ,0.9 mmol/L (OR 16.69; 95% CI: 4.64–76.35; OR 7.23; 95% CI: 1.86–32.63, respectively).
CONCLUSION: Metabolic syndrome is highly prevalent among hepatitis C virus–infected patients without type 2
diabetes or obesity. Metabolic syndrome was significantly associated with hypertension, insulin resistance, increased
abdominal fat, and overweight.
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INTRODUCTION
Over 170 million people worldwide, constituting 3% of
the global population, are infected with the hepatitis C virus
(HCV) (1). In Brazil, it is estimated that 1–2% of the national
population is infected with HCV (2,3).
HCV infection increases oxidative stress, tissue damage,
and pro-inflammatory cytokine secretion, all of which
contribute to progressive fibrosis, cirrhosis, cancer, and
liver failure (4,5). Chronic hepatitis C is associated with
significant morbidity and mortality and is the main reason
for liver transplants in the developed world (6).
Recent data suggest a close relationship between HCV
infection and metabolic syndrome (7). It is possible that
HCV infection causes fatty liver disease, a precursor of
hepatic steatosis, which is a recognized component of
metabolic syndrome (8). Individual components of meta-
bolic syndrome are independent predictors of mortality in
patients with chronic liver disease, including those infected
with HCV (9).
Metabolic syndrome is more prevalent among patients
with type 2 diabetes and obesity. However, there are no data
regarding metabolic syndrome in non-obese, non-diabetic
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219patients with chronic hepatitis C. In this study, we evaluated
the prevalence of metabolic syndrome and its risk predictors
in HCV genotype 1–infected patients who do not have
obesity or type 2 diabetes.
METHODS
This cross-sectional study included 125 HCV genotype 1–
infected patients who attended theNutritionandHepatology
Clinic at the Hospital of the Federal University of Bahia. We
recruited treatment-naive patients, as well as nonresponders
and relapsers to antiviral therapy. All patients were over 18
years of age, consumed less than 20 g/day of alcohol and
were not taking antiviral therapy or had discontinued
antiviral therapy for at least three months. HCV infection
was diagnosed by the presence of serum antibodies to HCV
(anti-HCV), which was confirmed by qualitative determina-
tion of HCV RNA. Reverse transcription–polymerase chain
reaction (RT-PCR) was performed on all samples to quantify
the HCV RNA.
Patients with diabetes mellitus or obesity(BMI.30 kg/m
2)
were excluded. Additionally, pregnant women and patients
with HIV, HBV, renal failure, heart disease, decompensated
cirrhosis, or malignancy were also excluded from the study.
All subjects signed a written informed consent. The study
was approved by the ethics commitee of Federal University
of Bahia according to the Declaration of Helsinki.
Complete demographic and social history data were
obtained from all patients. Clinical data, such as diagnosis,
viral genotype, necroinflammatory index, and presence of
fibrosis, were collected from the patients’ medical records.
Anthropometric data, including body weight, height, and
waist circumference, were measured according to standar-
dized procedures. Waist circumference (WC) was measured
according to World Health Organization (WHO) recom-
mendations (10).
Waist circumference was measured at the midpoint
between the superior aspect of the iliac crests and the lower
lateral margins of the ribs using an inelastic tape (TBW
Import Ltd) that was 0.5 cm in width and 200 cm in length.
Additionally, multicompartmental bioimpedance analysis
(model Inbody 520H) was performed according to the
manufacturer’s instructions. For men and women, body fat
percentages $25% and $32%, respectively, were considered
to increase the risk for obesity-related comorbidities (11).
After a 12-hour fast, blood samples were collected to
determine serum aspartate aminotransferase (AST), alanine
aminotransferase (ALT), gamma-glutamyl transferase (cGT),
alkaline phosphatase (ALP), plasma glucose, insulin, trigly-
ceride, total cholesterol, and lipoprotein fraction levels.
Analyses were performed using Beckman Coulter LX20
PROequipmentanda CX-9 ChemistryAnalyzer withLabtest
kits. Serum insulin was measured by the electrochemilumi-
nescence method using Elecsys 2010 equipment (Roche Kit).
The insulin resistance index was calculated according to
the Homeostasis Model Assessment of Insulin Resistance
(HOMA-IR): HOMA-IR=fasting insulinemia (microU/mL)
x fasting glycemia (mmol/L)/22.5) (12).
Patients underwent abdominal ultrasonography with
one of three radiologists using a single machine. Hepatic
steatosis was graded as mild, moderate or severe according
to the classification of Saverumuttu et al. (13).
Metabolic syndrome was defined based on the Inter-
national Diabetes Federation (IDF) criteria, including the
presence of a waist circumference $90 cm for men and
$80 cm for women plus at least two of the following: arterial
blood pressure $130/85 mmHg or taking medications for
blood pressure, triglycerides $150 mg/dl or taking fibrates,
HDL cholesterol ,40 mg/dl for men and ,50 mg/dl for
women or taking pharmacological therapy, and fasting
glucose $100 mg/dl or a diagnosis of diabetes (14).
The cut-off points adopted for classifying central obesity
as a predictor of increased risk for metabolic syndrome were
a waist circumference .88 cm for women and .102 cm for
men; these cut-offs are associated with a substantially
increased risk of metabolic complications according to the
WHO (10). Abdominal obesity was further defined as a
waist:hip ratio (WHR) .0.90 for men and .0.85 for women.
An increased WHR is associated with greater cardiovascular
risk (10,15).
We used the medical record to determine whether
patients had arterial hypertension. This determination
included subjects who had been previously diagnosed with
hypertension by their clinicians and all patients who were
under pharmacological treatment.
All data were analyzed using statistical package R version
2.12 (16). Statistical analysis was performed using the
Mann–Whitney test for comparisons of continuous variables
between groups and the corrected Fisher’s exact test for
comparisons of frequencies. Logistic regression analysis was
used to evaluate risk predictors for metabolic syndrome. A
two-tailed p-value ,0.05 was considered to be statistically
significant.
RESULTS
Patient Characteristics and Prevalence of Metabolic
Syndrome
Metabolic syndrome was diagnosed in 21.6% of the
patients with HCV. The mean age was 53.3 years (¡10.5
years), and 78 (62.4%) of the patients were male.
Additionally, 74 patients (59.2%) had previously undergone
antiviral treatment, and 51 (40.8%) were treatment-naive.
Table 1 shows the prevalence of metabolic syndrome (MS)
and the demographic, clinical, and anthropometric char-
acteristics of the patients. Women had a higher prevalence
of MS (55.6%). Among patients with metabolic syndrome,
hypertension was present in 59.3%, HOMA-IR $3 was
present in 77.8%, 85.2% were overweight, 48.1% had an
increased waist circumference, 85.2% had an increased body
fat percentage, and 92.3% had an elevated waist:hip ratio.
There was no significant association between metabolic
syndrome and hepatic steatosis, degree of liver fibrosis, age
or previous treatment (nonresponders/relapsers vs. treat-
ment-naive; p=0.508). The distribution of treatment-naive
patients vs. nonresponders/relapsers was similar for those
with and without MS (Table 1). Of note, after logistic
regression analysis, previous antiviral treatment did not
appear to be a risk factor for metabolic syndrome.
Individuals with metabolic syndrome had significantly
higher fasting glucose (p=0.0005), fasting insulin (p,0.0001),
HOMA-IR (p,0.0001), and triglycerides (p=0.0003) and
lower HDL (p=0.006) (Table 2).
Predictors of Metabolic Syndrome
Bivariate analyses of risk factors for metabolic syndrome
in this population are shown in Table 3. Women were 2.5
times more likely to have MS (OR 2.58; 95% CI: 1.09–6.25),
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have MS (OR 2.63; 95% CI: 1.04–7.29). Fasting hyperglycemia
(OR 8.05; 95% CI: 3.17–21.32), hypertriglyceridemia (OR 7.91;
95% CI: 2.88–22.71), and abnormal waist circumference (OR
10.33; 95% CI: 3.72–30.67) were major contributors to MS.
Overweight (OR 11.33; 95% CI: 3.97–41.07) and increased
body fat percentage (OR 8.34; 95% CI: 2.94–30.08) also
contributed to metabolic syndrome. Using the final multi-
variate regression model, similar results were observed for
abdominalfat(OR 9.98;95% CI:2.63–44.41)andtotalbody-fat
percentage (OR 8.73; 95% CI: 2.33–42.34). However, MS risk
was higher for those with blood glucose $5.55 mmol/L and
those with HDL cholesterol ,0.9 mmol/L (OR 16.69; 95%
CI: 4.64–76.35; OR 7.23; 95% CI: 1.86–32.63, respectively)
(Table 4).
DISCUSSION
The prevalence of metabolic syndrome in our study was
21.6%, which is similar to the prevalence of 24.7% found by
Huang et al. using the same IDF criteria. Indeed their study
did not exclude diabetic and obese patients (17).
When the NCEP/ATPIII criteria were used, only 12.1% of
the patients were diagnosed with metabolic syndrome (data
not shown). Serste ´ et al. (2010) found similar results (12.4%)
in a large cohort of patients with chronic hepatitis C (18).
The NCEP/ATPIII criteria would not have diagnosed
almost 9.5% of the individuals with MS who were
diagnosed using the IDF definition (12.1% vs. 21.6%;
p,0.006). Therefore, we chose to use the IDF definition of
metabolic syndrome, which adopts lower waist circumfer-
ence and fasting glucose cut-offs to define obesity and
hyperglycemia.
It should be noted that even after excluding patients with
diabetes and obesity, there was a high prevalence of
metabolic syndrome among patients with chronic hepatitis
C. These patients also presented a significantly higher
percentage of total body fat, waist circumference, waist:hip
ratio and BMI compared to those without MS. In the present
study, MS patients had significantly higher BMI than others.
These results are in agreement with a study conducted in
Taiwan that demonstrated that patients with hepatitis B and
C and MS, as defined by NCEP/ATP III criteria, had higher
BMI compared to those without MS (19).
Table 1 - Demographic, anthropometric, clinical, and histological data in patients with chronic HCV infection.
Metabolic syndrome
Yes (n=27) No (n=98) Total p-value
*
n (%) n (%) n
Sex
Male 12 (44.4) 66 (67.3) 78 0.043
Female 15 (55.6) 32 (32.7) 47
Age
,60 19 (70.4) 69 (70.4) 88 1.000
$60 8 (29.6) 29 (29.6) 37
Antiviral treatment status
Naive 9 (33.3) 42 (42.9) 51 0.507
Nonresponders/relapsers 18 (66.7) 56 (57.1) 74
Stage of fibrosis on liver biopsy
F0-F2 13 (56.5) 47 (61.0) 60 0.809
F3-F4 10 (43.5) 30 (39.0) 40
Hepatic steatosis detected by abdominal
ultrasound
No 10 (52.6) 53 (67.9) 63 0.283
Yes 9 (47.4) 25 (32.1) 34
Systemic arterial hypertension
No 11 (40.7) 76 (77.6) 87 ,0.001
Yes 16 (59.3) 22 (22.4) 38
HOMA-IR
,3.0 6 (22.2) 73 (74.5) 79 ,0.001
$3.0 21 (77.8) 25 (25.5) 46
Body mass index
,25 kg/m
2 4 (14.8) 65 (66.3) 69 ,0.001
25–30.0 kg/m
2 23 (85.2) 33 (33.7) 56
Waist circumference
a
Adequate 14 (51.9) 89 (90.8) 103 ,0.001
Elevated 13 (48.1) 9 (9.2) 22
Waist:hip ratio
b
Adequate 1 (3.7) 39 (39.8) 40 ,0.001
Elevated 26 (92.3) 59 (60.2) 85
Body fat percentage
c
Adequate 4 (14.8) 58 (59.2) 62 ,0.001
Elevated 23 (85.2) 40 (40.8) 63
*Fisher’s exact test.
aAdequate WC: #88 cm for women and #102 cm for men.
bAdequate WHR: #85 cm for women and #90 cm for men.
cAdequate BF%: ,32 cm for women and ,25 cm for men.
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may induce changes in body weight, insulin resistance and
serum lipid levels. However, all previously treated patients
in our study had stopped receiving treatment for at least 3
monthsand thereforewerenotundertheeffectsofinterferon.
In the absence of MS, patients usually had an appropriate
BMI and body-fat percentage and normal insulin sensitivity.
We found a mean HOMA-IR .3.0 in patients with MS. This
finding is in agreement with a study by Grigoresceu et al. (20)
of treatment-naive patients with HCV, which found signifi-
cantly higher HOMA-IR values in patients with MS (7.88 vs.
4.29).However,thoseauthorsobservedametabolicsyndrome
prevalence of 61.48% using the IDF criteria. We speculate that
this higher MS prevalence may be explained by the inclusion
of obese patients and a greater proportion of women (65.4%);
our study excluded obese subjects, and only 37.4% of our
patients were women. Furthermore, those authors used a
HOMA-IR value $2.0 to define insulin resistance and a value
of $4 to diagnose a pre-diabetic state. If we had used those
cut-off values, we would have found that most patients with
hepatitisC and HOMA-IR values between2 and 3 had insulin
resistance, rather than metabolic syndrome. In addition, half
of our patients with MS had a HOMA-IR value $4 and would
have been considered pre-diabetic.
HCV proteins can activate TNF-a expression and inhibit
the function of insulin receptor substrate (IRS) proteins,
which contribute to insulin resistance by decreasing glucose
transporter (GLUT-4) expression and lipoprotein lipase in
peripheral tissues (21). Insulin resistance has frequently been
associated with steatosis, fibrosis progression and lower
response to HCV antiviral therapy with PEGylated interferon
and ribavirin (22-25). The data from this study suggest that
the evaluation of HOMA-IR in certain patients with HCV,
especially those who are overweight, might be beneficial in
the early detection of abnormal glucose metabolism in this
population.
In our evaluation of independent risk factors for metabolic
syndrome, overweight individuals were 11 times more likely
to develop MS than were non-overweight patients. When the
body fat percentage criteria were considered, the risk for
developing metabolic syndrome was 8.3 times higher. These
data highlight the importance of body composition analysis
in screening for metabolic syndrome and the importance of
using a sensitive cut-off for diagnosing abdominal obesity,
such as the one suggested by the IDF.
Our study also found that cGT $85 U/L was an
independent predictor of MS; these data are consistent with
the results observed by Lee et al. in the participants of the
Framingham study. The authors found that an increase in
serum cGT predicts the onset of metabolic syndrome,
cardiovascular disease, and death, suggesting that cGT is
a marker of metabolic and cardiovascular risk (26).
Although cGT is commonly used in clinical practice as an
indicator of hepatobiliary disease and active ethanol con-
sumption, this enzyme might also be used as a biomarker for
metabolic syndrome and cardiovascular risk and is strongly
associated with insulin resistance (27). Insulin resistance, type
2 diabetes, hypertension, obesity, and metabolic syndrome
are independent predictors of mortality in individuals with
hepatitis C (9,28). Our study was a cross-sectional study of
adultswithchronicHCVinfection whoweredividedintotwo
groups based on whether they had metabolic syndrome.
Therefore, this study did not have a sex- and age-matched
control group.
In conclusion, our study showed that 21.6% of patients
infected with HCV genotype 1 had MS. MS was significantly
associated with hypertension, insulin resistance, increased
Table 4 - Multivariate analysis for predictors of metabolic
syndrome in patients with chronic HCV infection.
Adjusted OR
* (95% CI) p-value
Waist circumference
a
Elevated 9.98 (2.63-44.41) 0.0012
Body fat percentage
b
Elevated 8.73 (2.33-42.34) 0.0029
Fasting glucose
$5.55 mmol/L 16.69 (4.64-76.35) ,0.0001
HDL-c
,0.9 mmol/L 7.23 (1.86-32.63) 0.0059
*OR adjusted for other variables shown.
aElevated WC: .88 cm for women and . cm for men.
bElevated BF%: $32% for women and $25 % for men.
Table 2 - Median values for biochemical tests and HOMA-
IR in patients with chronic HCV infection.
Metabolic syndrome
Yes (n=27) No (n=98) p-value*
md i iq md i iq
Total cholesterol (mmol/L)
1 3.47 1.27 4.07 1.18 0.4009
LDL-c (mmol/L)
1 1.99 1.13 2.45 1.09 0.2493
HDL-c (mmol/L)
1 1.04 0.37 1.17 0.40 0.0063
Triglycerides (mmol/L)
2 1.56 0.75 0.99 0.56 0.0003
Aspartate Aminotransferase (U/L) 71.0 47.7 53.5 43.7 0.1778
Alanine Aminotransferase (U/L) 81.0 41.5 68.0 47.0 0.2282
Gamma Glutamyl Transferase (U/L) 138.0 96.0 83.0 110.0 0.0974
Alkaline Phosphatase (U/L) 91.0 32.0 80.0 55.5 0.7982
HOMA-IR 4.3 2.2 2.03 1.7 ,0.0001
Fasting Insulin (pmol/L)
3 108.3 57.6 61.7 49.3 ,0.0001
Fasting Glucose (mmol/L)
4 5.72 1.22 4.99 0.65 0.0005
Body Mass Index (kg/m
2) 27.8 3.1 23.7 4.0 ,0.0001
*Mann-Whitney test.
1mg/dL (40.0259),
2 mg/dL (40.0113),
3 mIU/mL(46.945),
4 mg/dL (40.0555).
Table 3 - Independent predictors of metabolic syndrome
in patients with chronic HCV infection.
Crude OR (95% CI) p-value
Sex
Female 2.58 (1.09-6.25) 0.0326
cGT
$85 U/L 2.63 (1.04-7.29) 0.048
Fasting glucose
$5.55 mmol/L 8.05 (3.17-21.32) ,0.001
HOMA-IR
$3.0 10.22 (3.90-30.54) ,0.001
HDL-c
,0.9 mmol/L 2.80 (1.07-7.16) 0.0316
Triglycerides
$1.7 mmol/L 7.91 (2.88-22.71) ,0.001
Body mass index
25 - 30 kg/m
2 11.33 (3.97-41.07) ,0.001
Waist circumference
a
Elevated 10.33 (3.72-30.67) ,0.001
Body fat percentage
b
Elevated 8.34 (2.94-30.08) 0.01
aElevated WC: . 88 cm for women and . 102 cm for men.
bElevated BF%: $ 32 cm for women and $ 25 cm for men.
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222abdominal fat, and overweight. Therefore, frequent monitor-
ing for insulin resistance and weight gain among patients
with HCV is beneficial because these clinical conditions can
negatively affect disease prognosis. Maintaining a healthy
body weight is important because it reduces the incidence of
comorbidities and possibly delays the progression of chronic
liver disease. Further studies are needed to evaluate whether
aninterventioninvolvinglifestylemodificationsand/ordrug
treatments for MS components can improve the response to
antiviral treatments in these patients.
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